UP!

CERE $0.4   View long term graphs

Ceres, Inc.
Type
Public
(Acquisition by Land O'Lakes pending)
Traded as NASDAQ: CERE
Industry Biotechnology
Founded 1996
Headquarters Thousand Oaks, California, United States
Key people
Richard Hamilton (President and CEO)
Products Seeds of energy crops
Subsidiaries Ceres Sementes do Brasil
Website ceres.net

Ceres, Inc. is a biotechnology company based in Thousand Oaks, California, United States. The company develops and produces seeds of genetically modified crops used for biofuels production. In addition to the operations in the United States, it has a subsidiary in Brazil called Ceres Sementes do Brasil.

The company was founded in 1996. Since 2012 it is listed at the NASDAQ. As of February 2012, the largest shareholders were Artal Luxembourg, Warburg Pincus, Ambergate Trust and Oxford Bioscience, while biotechnology company Monsanto had 4.8% stake. The company's president and CEO is Richard Hamilton.

On June 21, 2016, Ceres was acquired by Land O'Lakes for $17.2 million.

Ceres sells sweet sorghum, switchgrass and high biomass sorghum seeds, with its first sales coming for the 2009 growing season. It has tested biofuels production from switchgrass and miscanthus. In 2010, Ceres started to cooperate with Novozymes to improve the enzyme cocktails for biorefinery switchgrass and sweet sorghum. USAID has funded Ceres' research on biotech traits and trait stacks in rice for Asia.

Q reports

Period Date Adjusted Actuals EPS GAAP EPS
Q4 2016 2016-10-14 Future report Set alerts
Q3 2016 2016-07-14 0.00 0.00
Q2 2016 2016-04-14 0.00 -0.09
Q1 2016 2016-01-14 0.00 -0.39
Q4 2015 2015-11-23 0.00 -1.25
Q3 2015 2015-07-10 0.00 -0.98
Q2 2015 2015-04-09 0.00 -1.36
Q1 2015 2015-01-13 0.00 -0.96
Q4 2014 2014-11-20 0.00 -1.04
Q3 2014 2014-07-10 0.00 -1.36

Ratings

2026-12-18
2014-01-10 Lower Price Target Barclays Overweight $9.00 to $5.00
2013-11-25 Downgrade Sidoti Buy to Neutral
2013-04-17 Reiterated Barclays Overweight $11 to $13
2013-01-11 Reiterated Barclays Overweight $16 to $13
2012-06-08 Initiated Barclays Overweight $18
1970-01-01
2026-12-18
2014-01-10 Lower Price Target Barclays Overweight $9.00 to $5.00
2013-11-25 Downgrade Sidoti Buy to Neutral
2013-04-17 Reiterated Barclays Overweight $11 to $13
2013-01-11 Reiterated Barclays Overweight $16 to $13

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Funds

In CERE 0 funds of 2183 total. Show all

Fund name Ticker shares

Major Shareholders

Name Relationship Total Shares Holding stocks
ARTAL LUXEMBOURG S A 17.00%  (8192167) CERE /
Krieger David Benjamin 5.11%  (2460807) CERE / KOS /
Ambergate Trust 5.09%  (2452366) CERE /
Pennell Roger Ivan VP of Trait Development 0.18%  (85233) CERE /
Gwyn Joseph Jefferson VP of Breeding and Genomics 0.10%  (49033) CERE /
Olivier de Vezin Edmund Martin 0.05%  (25896) CERE /
KILEY THOMAS 0.03%  (16666) CERE / GERN / TSPT /
Carlson Robert W Jr. See Remarks 0.02%  (9500) CERE /

Comments